Clinical Trials Sponsored by Aerocrine AB

Total 1056 results

Aerocrine AB

Completed

NIOX VERO Nasal Application in Primary Ciliary Dyskinesia

PCD

France, United States, Denmark, Germany
Aerocrine AB

Completed

Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Aerocrine AB

Completed

Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms

Asthma

United States
Aerocrine AB

Completed

Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment (eNOugh)

Asthma

Sweden, United Kingdom
Aerocrine AB

Unknown

Measurement of FeNO in Young Children With the NIOX VERO

Asthma

United States
Aerocrine AB

Completed

A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma

Asthma

United States
Aerocrine AB

Completed

Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age

Asthma

United States
University of Leicester
Aerocrine AB

Completed

Childhood Asthma Management in Primary Care: Implementation Of Exhaled Nitric Oxide and Spirometry Testing (CHAMPIONS)

Asthma

United Kingdom
Vanderbilt University Medical Center
Aerocrine AB

Withdrawn

Smartphone-facilitated Asthma Control (SNAPP)

Childhood Asthma

United States
Orion Corporation, Orion Pharma
Aerocrine AB

Terminated

Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home (OCTAGEN)

Asthma

Sweden
Research in Real-Life Ltd
Aerocrine AB

Completed

The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms (NSRS)

Asthma

United Kingdom
Research in Real-Life Ltd
Aerocrine AB

Suspended

Exhaled Nitric Oxide in Asthma Management

Asthma

United Kingdom
Hull University Teaching Hospitals NHS Trust
Aerocrine AB

Completed

The Utility of feNO in the Differential Diagnosis of Chronic Cough (TUF)

Cough

United Kingdom
University Hospital, Antwerp
Merck Sharp & Dohme LLC; Aerocrine AB

Completed

Monitoring Asthma Treatment Using Exhaled Nitric Oxide (NOASTHMA)

Asthma

Belgium
Wake Forest University
Aerocrine AB

Terminated

Evaluation of FeNO During and Following Acute COPD Exacerbation

Chronic Obstructive Pulmonary Disease

United States
Belfast Health and Social Care Trust
Hoffmann-La Roche; Medical Research Council; Aerocrine AB

Completed

A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma

Severe Persistent Asthma

United Kingdom
Airsonett AB
Commitum AB; Croel AB

Completed

Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma (4A)

Asthma

Denmark, United Kingdom, Norway, Sweden, Germany, Finland
Amplicon AB

Recruiting

Study to Assess PK, PD, Nicotine Extraction, Palatability, Subjective Effects of Nicotine Pouches - Daily Nicotine Users

Nicotine Use Disorder

Sweden
Aventure AB
Glucanova AB

Completed

Effects of a Whole Grain Cereal Product on Blood Glucose Response After 3 Consecutive Meals

Blood Glucose

Sweden
Ostomycure AB
Devicia AB

Unknown

Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy

Ileostomy - Stoma

Sweden, United Kingdom
DermaGen AB
Pergamum AB

Completed

A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis

Acute Otitis Externa

Sweden
Neurocrine Biosciences

Recruiting

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

SCN8A Developmental and Epileptic Encephalopathy Syndrome

United States
Neurocrine Biosciences

Enrolling by invitation

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

SCN8A Developmental and Epileptic Encephalopathy Syndrome

United States
Neurocrine Biosciences

Active, not recruiting

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Congenital Adrenal Hyperplasia

United States, United Kingdom, France, Greece, Italy, Spain, Belgium, Canada, Germany, Poland
Neurocrine Biosciences

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia (ERUDITE)

Schizophrenia

United States, Spain, Serbia, Czechia, Bulgaria, Mexico
Neurocrine Biosciences

Completed

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) (SAVITRI)

Major Depressive Disorder

United States, Czechia, Bulgaria, Poland, Slovakia, Sweden
Neurocrine Biosciences

Completed

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD (TERPSIS)

Anhedonia | Major Depressive Disorder

United States, Puerto Rico
Neurocrine Biosciences

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Epileptic Encephalopathy | Continuous Spike and Wave During Sleep

United States, Denmark, Spain, Switzerland, United Kingdom, Canada
Neurocrine Biosciences

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

CAH - Congenital Adrenal Hyperplasia

United States
Neurocrine Biosciences

Terminated

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia (TD)

United States, Puerto Rico
Neurocrine Biosciences

Completed

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia

United States
Neurocrine Biosciences

Completed

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Tardive Dyskinesia

United States, Puerto Rico
Neurocrine Biosciences

Completed

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia

United States, Puerto Rico
Neurocrine Biosciences

Completed

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Tardive Dyskinesia

United States
Karolinska Institutet
Merck Sharp & Dohme LLC; Uppsala University; The Swedish Research Council; Region... and other collaborators

Completed

Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

Allergic Asthma

Sweden
Neurocrine Biosciences

Recruiting

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Neurocrine Biosciences

Enrolling by invitation

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Chorea, Huntington

Canada
Neurocrine Biosciences

Active, not recruiting

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst)

Congenital Adrenal Hyperplasia

United States, Spain, Belgium, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Serbia, Sweden, United Kingdom
Neurocrine Biosciences

Completed

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Focal Onset Seizure | Focal Onset Epilepsy

Spain, Belgium, Czechia, France, Italy, Australia, Hungary, United Kingdom
Neurocrine Biosciences

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia

CAH - Congenital Adrenal Hyperplasia

United States
Neurocrine Biosciences

Completed

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Neurocrine Biosciences

Withdrawn

An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

Insomnia

United States
Neurocrine Biosciences

Completed

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

United States
Neurocrine Biosciences

Completed

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

United States

3

Subscribe